January 2022

Maria Themeli, Amsterdam AMC, T cell sensitivity and persistence, blood cancers, z-Movi, Cell Avidity analysis

New study published in Translational Medicine highlights cell avidity’s power as a functional biomarker for improved CAR-T design in preventing tumor escape

Using cell avidity measurements and traditional immuno-assays, the researchers successfully demonstrated that co-expression of costimulatory receptors along with an FDA approved BCMA and CD19 CAR can improve both durability of potential treatments as well as persistence for common blood cancers.

j.yeh23 January 2022

Press releases

LUMICKS Announces the Installation of its Quadruple C-Trap^® Instrument at Rockefeller University to Expand Fundamental Research of DNA Processes

The C-Trap will support the research of Prof. Michael O’Donnell to investigate the mechanisms of DNA replication. Between O’Donnell and his collaborator Prof Shixin Liu, Rockefeller University will use the C-Trap to unveil the mechanisms of many types of enzymes, such as multi-protein DNA replicating machines of bacteria and eukaryotes.

j.yeh11 January 2022

Press releases

LUMICKS Announces Adoption of z-Movi® Cell Avidity Analyzer by Two Major Centres for Cancer Immunology

LUMICKS announced today that two major centers of excellence in cancer immunology, Fred Hutchinson Cancer Research Center and Oxford University, have adopted the z-Movi Cell Avidity Analyzer instrument for the development of promising immunotherapeutic strategies.

j.yeh10 January 2022

Join our newsletter